Filter By
Search
-
INTEGRAGEN PRESENTS RESULTS OF A STUDY EXTENDING THE IMPACT OF MIR-31 EXPRESSION MEASUREMENT TO STAGE III COLON CANCER PATIENTS AT ESMO 2018
Analysis of samples from the PETACC 8 phase III clinical trial shows that the...
-
INTEGRAGEN NOMINATED FOR THE GALIEN MEDSTARTUP AWARD 2018
IntegraGen has been nominated for the Prix Galien MedStartup 2018, a joint initiative between the...
-
GOPATH LABORATORIES ANNOUNCE THE LAUNCH OF THE MIR-31NOW TEST
GoPath Laboratories today announced the launch of a new proprietary test, miR31nowTM, to coincide with...
-
INTEGRAGEN PARTICIPATES IN THE ASCO 2018 AMERICAN CANCER CONGRESS HELD IN CHICAGO FROM JUNE 1 TO 5
The annual ASCO meeting brings together more than 32,000 cancer specialists from around the world to...
-
PUBLICATION IN BIOMARKER INSIGHTS OF TECHNICAL VALIDATION DATA FOR THE MIR-31-3P TEST
IntegraGen is pleased to announce that a full summary of the results of the validation studies for...
-
INTEGRAGEN: A STRUCTURING DOUBLE AGREEMENT WITH TWIST BIOSCIENCE - INTERVIEW WITH BERNARD COURTIEU IN BIOTECH FINANCE
Bernard Courtieu answers questions from Pierre-Louis Germain, "Biotech Finance" specialist journalist, about the...
-
PRESENTATION OF NEW RESULTS ON THE MIR-31-3P BIOMARKER IN AN ORAL PRESENTATION AT THE ESMO 2016 CONGRESS IN COPENHAGEN
The results of new analyses carried out on the FIRE-3 trial on the predictive role of the marker...
-
RESULTS OF MIR-31-3P EXPRESSION ANALYSIS IN THE FIRE-3 STUDY TO BE PRESENTED AT THE ASCO 2016 CONGRESS
he results of mir31-3p expression analysis in the FIRE-3 colon cancer study...
-
INTEGRAGEN CONVENES SCIENTIFIC COMMITTEE TO REVIEW LATEST MIR-31-3P CLINICAL DATA
IntegraGen convened its Oncology Scientific Committee at the 2016 Gastro Intestinal Symposium in...
